Background. The World Health Organization (WHO) recommends the discontinuation of oral poliovirus vaccine after eradication of wild poliovirus. Studies assessing inactivated poliovirus vaccine (IPV) immunogenicity in tropical countries, using the WHO Expanded Programme on Immunization (EPI) schedule, have been limited.
In countries where poliomyelitis is endemic, the routine poliomyelitis immunization schedule currently recommended by the World Health Organization (WHO) Expanded Programme on Immunization (EPI) includes 4 doses of oral poliovirus vaccine (OPV), to be given at birth and at 6, 10, and 14 weeks of age; the dose at birth is excluded in countries where poliomyelitis is not endemic [1] . Inactivated poliovirus vaccine (IPV) is considered to be safer than OPV because IPV is not associated with the rare risk of vaccine-associated paralytic poliomyelitis (VAPP) [2, 3] or with the emergence of neurovirulent vaccine-derived poliovirus (VDPV) [4] [5] [6] [7] [8] . Some industrialized countries, such as Sweden, Finland, and The Netherlands, have chosen to use IPV instead of OPV [9] . In the United States, an all-IPV schedule was adopted in 2000 and is recommended at 2, 4, and 6-18 months of age and at 4-6 years of age [10] .
The WHO Polio Eradication Strategic Plan for 2004-2008 recommends the discontinuation of vaccination with OPV after global eradication of wild poliovirus [11, p. 22] . Thus, assessment of the performance of IPV, using the EPI-recommended schedule, is critical to the evaluation of future IPV use in routine immunization programs in the developing world [12] . Studies using the EPI schedule to assess the immunogenicity of IPV in tropical, developing countries have been limited. Moreover, interpretation of the results is difficult because circulation of OPV viruses or wild poliovirus may cause intestinal reinfection, boosting humoral and local immunity [13] and leading to overestimation of IPVinduced immunity.
In 2000, Puerto Rico replaced OPV with IPV in accordance with the US schedule recommended by the Advisory Committee on Immunization Practices (ACIP) [14] , making it one of the few tropical areas to exclusively use IPV for routine vaccination. The last case of wild polio in Puerto Rico was reported in 1974, and evidence of circulating wild poliovirus has not been found [15] .
We conducted a study in Puerto Rico to assess the serologic response to IPV in infants in a tropical setting after vaccination with 3 doses of IPV, at 6, 10, and 14 weeks of age (i.e., the EPI schedule) and at 8, 16, and 24 weeks of age (i.e., the US schedule [2, 4, and 6 months]), to determine the implications for future IPV-vaccination policy recommendations in countries currently using the EPI schedule.
METHODS

Study design and participants.
We conducted a randomized clinical trial in San Lucas Hospital in Ponce, Puerto Rico, between 1 July 2003 and 17 September 2004. Infants were enrolled in the study before being discharged from the hospital after birth. Enrollment inclusion criteria included being a full-term healthy infant (37-42 weeks gestation); being placed in the wellbaby nursery; and having parents or guardians who were expected to live in Puerto Rico for the following 8 months, who were not expected to travel to a country known to have circulating poliovirus or to use OPV, and who provided informed consent for the infant's participation in the study.
A total of 916 infants were born at San Lucas Hospital during the study period. Of these, 764 (83.4%) were full term and were placed in the well-baby nursery after birth. Interviews to assess other enrollment criteria were conducted among the parents or guardians of 710 (92.9%) of these newborns. After exclusion of 141 infants whose parents or guardians refused to participate and 4 infants who did not meet other enrollment criteria, 565 (79.6%) infants were enrolled in the study and randomized to a study arm (283 were assigned to the US arm and 282 to the EPI arm). Of the 565 enrolled infants, 68 were excluded because they did not attend the first visit. Of the 497 infants who started the study as assigned, 24 were withdrawn. Of the 473 infants who completed the study, 18 were excluded from the analysis owing to deviation from the scheduled vaccination window; therefore, 455 infants (230 in the US arm and 225 in the EPI arm) completed the study and were included in the analysis (figure 1).
Intervention and follow-up. After enrollment, infants were randomized into 1 of 2 arms: (1) those in the EPI arm received IPV at ages 6, 10, and 14 weeks (this schedule is also approved for use in the United States if an accelerated schedule is needed [16] ), and (2) those in the US arm received IPV at ages 8, 16, and 24 weeks. For infants in the US arm, vaccination dates were allowed to vary from the scheduled IPV vaccination date by no more than 4 days before or after the scheduled vaccination date. For infants in the EPI arm, vaccination dates were allowed to vary from the scheduled vaccination date by no more than 4 days after that scheduled date, to maintain a minimum of 4 weeks between vaccinations, in accordance with ACIP recommendations [16] . In addition, infants in both arms received all other vaccines in accordance with the Puerto Rico Immunization Schedule [10] . IPV was the only vaccine administered in the right thigh, in order to assess differences in local reactogenicity between study arms. Serum samples were collected prior to the first IPV dose and 28-45 days after the third IPV dose. Each child was seen 4 times: once for each of the 3 doses and once to obtain a postvaccination blood specimen. For children without seroconversion to at least 1 of the 3 poliovirus types, a fourth dose of IPV was administered. Enrolled infants were withdrawn from the study if requested by the parent, a study visit was missed or a study visit did not take place within the specified time window, any vaccines were received outside the study (except for a dose of hepatitis B vaccine at birth), or the infant had a contraindication to receiving IPV before completing the 3rd dose or was found to have an immunodeficiency illness that might interfere with vaccine response.
The study protocol was reviewed and approved by institutional review boards of the Centers for Disease Control and Prevention (CDC) and the Ponce School of Medicine in Puerto Rico. The study was conducted according to the Health Insurance Portability and Accountability Act of 1996. The clinical trial is registered at ClinicalTrials.gov (under identifier NCT00137696; http://clinicaltrials.gov/ct/show/NCT00137696?orderp1).
Vaccines. Infants were vaccinated with a single lot of IPOL enhanced-potency IPV vaccine (Sanofi-Pasteur) containing the following 3 strains of poliovirus: type 1 (Mahoney), type 2 (MEF-1), and type 3 (Saukett). Each vaccine dose was 0. Data collection. During the enrollment interview, basic demographic information was collected. At each study visit, data were gathered about any vaccinations and all medications given outside the study, travel by household members outside Puerto Rico (to determine potential contact with wild poliovirus or OPV virus), and breast-feeding regimen (to determine if maternal antibodies transferred via breast milk interfered with seroconversion). Parents or guardians were given a diary to record, on a daily basis, local adverse reactions (i.e., erythema, swelling, hardness, warmth, pain, and/or tenderness) and general adverse reactions (i.e., fever, irritability, drowsiness, vomiting, tiredness, loss of appetite, rash, and/or crying for 13 h) for 7 days after vaccination. They were also given a ruler to measure the size of the local adverse reaction and a thermom- eter to assess fever. During visits 2, 3, and 4, adverse reactions to vaccination since the previous visit were determined from the diary. Specimen collection and laboratory testing. Blood specimens of at least 500 mL were obtained from study infants immediately preceding administration of the first IPV dose and 28-45 days after administration of the third IPV dose. Specimens were labeled with a unique identifier and stored at 2ЊC-8ЊC until serum separation, which was done on the day of collection. Serum specimens were aliquoted and stored at Ϫ80ЊC at the Ponce School of Medicine. All serum specimens were frozen and then sent to the CDC after collection of the second serum specimen, for all study participants; serum specimens were tested collectively for antibody titers for poliovirus types 1, 2, and 3.
Serum specimens were tested, at the CDC, for levels of neutralizing antibody titers against poliovirus types 1, 2, and 3 by means of a modified microneutralization assay [17] . Approximately 80-100 median TCID 50 of each vaccine virus serotype and serial dilutions of serum (starting at 1:8 and ending at 1 :1024) were incubated at 37ЊC for 2.5 h before Hep- at 37ЊC, each plate was stained with 0.05% crystal violet in 25% ethyl alcohol, with the optical density in each well measured by a spectrophotometer. Both specimens from an infant were tested in the same assay run, and each run contained multiple replicates of a standard antiserum, to assess multiplerun performance variation. Each specimen was run in triplicate, with the final titer estimated by use of the Spearman-Karber method [18] .
Sample-size calculation and statistical analyses. The study sample size was based on an estimate of a seroconversion rate of 85% [19] . To assume an 0.80 probability that the estimate from this study was in error by р10%, we used a single-tailed test with a 90% confidence interval (CI), based on the normal approximation of the binomial distribution. A sample size of at least 220 subjects per arm satisfied these criteria; however, we adopted an enrollment goal of 250 infants in each arm, to compensate for an expected attrition of ∼15%.
Seroconversion for each serotype was defined as a у4-fold increase in antibody titers between the projected residual level of maternally derived antibody and the level in the infant's postimmunization specimen, under the assumption of a halflife of 28 days for maternal antibody decay [19] . We validated this assumption by estimating the prevaccination titers at 8 weeks of age for infants in the EPI arm and comparing these adjusted titers with those for infants in the US arm. Prevaccination median titers obtained at 6 weeks of age for infants in the EPI arm were statistically significantly higher than those obtained at 8 weeks of age for infants in the US arm. However, after estimation of prevaccination titers at 8 weeks of age for the EPI arm, the median titers for both arms were not statistically significantly different, which validated our assumption. Antibody titers for the 3 poliovirus types were expressed as log 2 of the estimated titer end points. For purposes of calculating titer distributions, the unobserved titers (below and above the starting and ending dilutions) were assigned values of 2.5 (below) and 10.5 (above). Maternal antibody titers, assessed by means of the prevaccination titers, were classified as high (titer у64 [у6 log 2 titer]) or low (titer !64 [!6 log 2 titer]), to assess the influence of maternal antibodies on seroconversion rates and titers. Sensitivity analyses using different cutoff points were also performed, to assess the interference of maternal antibodies on seroconversion.
To test for differences in proportions, x 2 and Fisher's exact tests were used. Wilcoxon rank-sum test statistics were used to examine the impact of the change in vaccination schedule on antibody titers and titer distributions. Statistical significance was assessed at . P ! .05
RESULTS
Baseline characteristics.
Among the enrolled infants who completed the study, versus those who did not, no significant differences were found in randomization to study arm; infant's sex or race; or mother's age at delivery, number of pregnancies, income, living situation, or education. Most children who completed the study were white and first-born children (table 1) . Most mothers of infants who completed the study were 20-35 years old and were married or living with a partner, and almost half of the mothers had less than a high school education (table  1) . No significant differences in infant's sex or race; breast-feeding regimen; or mother's age at delivery, education, living situation, or income were detected between study arms (table 1) .
Seroconversion and median titers. Seroconversion rates for the EPI arm were 85.8% (95% CI, 80.5-90.1) for poliovirus type 1, 86.2% (95% CI, 81.0-90.4) for poliovirus type 2, and 96.9% (95% CI, 93.7-98.7) for poliovirus type 3. Seroconversion rates for the US arm were 99.6% (95% CI, 97.6-100), 100% (95% CI, 98.4-100%), and 99.1% (95% CI, 96.9-99.9) for poliovirus types 1, 2, and 3, respectively. Seroconversion rates for poliovirus types 1 and 2 were significantly higher ( ) in the US arm than in the EPI arm (figure 2). We P ! .001 did not find significant differences when the relationship between seroconversion for all types together and demographic or socioeconomic variables was analyzed.
Prevaccination median titers for poliovirus types 1 and 2 were significantly higher in the EPI arm than in the US arm (figure 3). Postvaccination median titers for poliovirus types 1, 2, and 3 were 9.5, 9.8, and 10.2, respectively, in the US armsignificantly higher than the 7.8, 7.2, and 9.5 values in the EPI arm (
; figure 3) . P ! .001 Influence of maternal antibody on seroconversion and median titers. A higher proportion of infants in the EPI arm had high levels of maternal antibody for all 3 poliovirus types (table 2). When seroconversion data for the US arm were stratified according to level of maternal antibody, high maternal antibody titers had little effect on seroconversion rates for any of the 3 poliovirus types. However, in the EPI arm, seroconversion rates were significantly lower among infants with high levels of maternal antibody for all 3 poliovirus types (P ! ; table 2). Similar results were obtained when sensitivity .001 analyses using different cutoff points were performed.
In both the US and EPI arms, postvaccination median titers were lower among infants with high maternal antibody titers for poliovirus type 1 (US arm, ; EPI arm, ), P ! .001 P p .001 type 2 (US arm, ; EPI arm, ), and type 3 (US P p .01 P p .003 arm, ; EPI arm, ) (table 2) . P p .04 P p .007 Adverse reactions. No statistically significant differences in terms of local or general adverse reactions were detected among infants vaccinated in either study arm. No serious adverse reactions were observed.
DISCUSSION
The findings in our study show that administration of IPV at 6, 10, and 14 weeks of age results in lower seroconversion rates against poliovirus types 1 and 2, when compared with vaccination at 8, 16, and 24 weeks of age. The response to IPV was highly sensitive to maternal antibody levels, particularly for infants vaccinated on the EPI schedule. Our findings also demonstrate that a vaccination schedule that starts at an early age and that has short intervals between doses reduces the serologic response to IPV.
Our findings of the effect of high levels of maternal antibody on reduction of the serologic response to IPV corroborates findings from other investigations [19] [20] [21] [22] . Although IPV administered at birth has shown to induce immunologic memory for an enhanced response to a later dose of IPV [23] , the results of some studies have suggested that administration of IPV at intervals !8 weeks may result in lower levels of serologic response [20, 21] . A study conducted in Cuba showed that 2 doses of IPV, administered at 8 and 16 weeks of age, performed better than 3 doses given at 6, 10, and 14 weeks of age, suggesting that vaccination at 8, 16, and 24 weeks of age would result in excellent seroconversion to IPV (CDC, unpublished data). In addition, decreased seroconversion rates due to shorter intervals between doses were further lowered by the presence of maternal antibodies. In a study conducted in India, infants 6-45 weeks of age were vaccinated at different ages with 3 doses of IPV, administered at 4-and 8-week intervals; seroconversion rates among the infants with detectable maternal antibody titers were 100%, 96.8%, and 87.5% against poliovirus types 1, 2, and 3, respectively, when the doses were given at 8-week intervals, compared with 94.4%, 46.2%, and 55.6%, respectively, when the doses were given at 4-week intervals [20] . In our study, seroconversion rates among children with high maternal antibody levels were 61.5%, 52.8%, and 73.3% against poliovirus types 1, 2, and 3, respectively, when vaccination was done on the EPI schedule. In our study, the higher seroconversion rates for poliovirus types 2 and 3 may be related to the fact that, in Puerto Rico, poliovirus immunity among women of childbearing age has been acquired only through vaccination, since wild poliovirus has not circulated since 1974 and since an all-IPV schedule has been in place since 2000 [14] . This may result in lower titers, compared with India, where wild poliovirus is still circulating [24] and where OPV is used both in frequent mass-immunization campaigns and in the routine immunization program, providing many opportunities for exposure to both vaccine and wild poliovirus.
The following limitations should be considered when interpreting our findings: (1) Pre-and postvaccination specimens were drawn from the infants at different ages in the US and EPI arms; therefore, the effect on seroconversion rates of an earlier start and a shorter vaccination interval could not be independently assessed. Nevertheless, reduced levels of seroconversion associated with earlier administration or shorter vaccination intervals were demonstrated by our sensitivity analyses, in which higher seroconversion rates were observed for the US arm regardless of the level of prevaccination titers. (2) Although seroconversion calculations were performed by using the same theoretical maternal antibody decay rate for both arms, seroconversion results for the EPI arm were more likely to be affected by this theoretical calculation. In fact, for the EPI arm, maternal antibody levels tended to be higher in the prevaccination specimen, because the specimens were obtained earlier and the interval between doses was shorter, allowing less time for maternal antibodies to decay before the postvaccination specimen was obtained. (3) We did not assess intestinal immunity through use of a live-virus challenge; therefore, we do not know whether the 2 schedules would result in differences in virus shedding after infection.
The results of this study are relevant in terms of informing current discussions on potential strategies for vaccination with IPV in the posteradication era. OPV became the vaccine of choice for eradication strategies recommended by the WHO following the World Health Assembly resolution in 1988 [25] , and extensive use of this vaccine has enabled a reduction in the number of endemic countries from 1125 in 1988 to 4 (i.e., Afghanistan, India, Nigeria, and Pakistan) by the beginning of 2006 [26] . Although continued wild poliovirus transmission continues to occur in these countries and an outbreak of poliomyelitis was recently reported in Namibia [27] , the WHO has recommended the discontinuation of routine vaccination with OPV in the posteradication era [28, 29] because of the risk of VAPP and the potential for outbreaks of VDPV infection. The Global Polio Eradication Initiative of the WHO is recommending a synchronized worldwide cessation of the routine use of all OPV at some point after interruption of wild poliovirus transmission [30] ; therefore, IPV will be the only vaccine available for routine immunization after that time [31] . For most developing, tropical countries that use the EPI schedule to administer OPV in conjunction with diphtheria and tetanus toxoids and pertussis vaccine, replacement of OPV by IPV with the same vaccination schedule may lead to a lower level of seroconversion and protection. Further research is needed to determine whether administration of the first dose of IPV at 6 weeks of age results in lower seroconversion rates, independent of the interval between doses. One option for increasing seroconversion rates would be to use a 6-10-or 10-14-week vaccination schedule for the first 2 doses, with administration of the 3rd dose at 9 months of age, when children usually receive measles-containing vaccine. A second option would be to administer a fourth dose of IPV later in life, following the 3-dose EPI schedule, to ensure better seroconversion rates [32] . A third option would be the administration of IPV through supplemental immunization activities (SIAs). In this case, special emphasis should be placed on the time elapsed between SIAs. Finally, a study in Senegal, which demonstrated 89% clinical efficacy with use of a 2-dose vaccination schedule with a 6-month interval between doses [33] , raised consideration of a 2-dose schedule with a first dose at 14 weeks of age and a second dose at 9 months of age.
This study is the first comparison of the serologic response to 3 doses of IPV when administered at 6, 10, and 14 weeks of age versus 8, 16, and 24 weeks of age in a tropical setting where wild poliovirus is not circulating and where OPV is not used. The results of this study are relevant for the planning of IPV use in a posteradication environment and should be considered in countries deciding to replace OPV with IPV, using the EPI-recommended schedule, in the posteradication era.
